News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phosphagenics Limited (POH.AX) Signs Global Agreement With Novartis Animal Health Inc. for Use of Transdermal Insulin in Companion Animals



3/31/2010 10:09:37 AM

MELBOURNE, Australia--(BUSINESS WIRE)--The Melbourne-based biotechnology company, Phosphagenics Limited (ASX:POH, OTCQX:PPGNY) announced today the signing of a global agreement to develop their patented transdermal (TPM) insulin delivery system for the treatment of diabetes in companion animals.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES